PT  - JOURNAL ARTICLE
AU  - An, Qiuying
AU  - Su, Yuhao
AU  - Wang, Yajing
AU  - Zhen, Chanjun
AU  - Bai, Wenwen
AU  - Fu, Liyuan
AU  - Liu, Yibing
AU  - Zhang, Ping
AU  - Zhou, Zhiguo
TI  - Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy?
AID  - 10.15537/smj.2024.45.9.20240045
DP  - 2024 Sep 01
TA  - Saudi Medical Journal
PG  - 900--910
VI  - 45
IP  - 9
4099  - http://smj.org.sa/content/45/9/900.short
4100  - http://smj.org.sa/content/45/9/900.full
SO  - Saudi Med J2024 Sep 01; 45
AB  - Objectives: To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT).Methods: The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patients were split into the adjuvant radiotherapy with or without chemotherapy (RT±CT) and the adjuvant chemotherapy (CT) groups. The process of propensity score matching (PSM) was employed.Results: Following PSM, 157 patients in total were recruited in each treatment group. There were no significant variations in either overall survival (OS) or cancer-specific survival (CSS) between the RT±CT and CT groups (median OS: 28 months versus. 51 months, p=0.063; median CSS: 31 months versus. 52 months, p=0.16). Within the CT group, patients with ypI/II or cI/II tumor stage, positive lymph node ratio (LNR) ≤0.1, and tumor size ≥50 mm (p<0.05) had higher OS compared to the RT±CT groups. Among patients with cT3-4 tumors in N-stage downstaging group, the OS and CSS were significantly greater for those underwent RT±CT as opposed to the CT group (5-year OS:56.6% versus 19.4%, p=0.042; 5-year CSS:67.9% versus. 19.4%, p=0.023). Multivariate Cox regression analysis identified the tumor histology grade as an independent prognostic factor of OS and CSS.Conclusion: Radiotherapy-based adjuvant therapy does not significantly improve the prognosis of EC patients after NCRT, although it may provide a survival benefit for patients with cT3-4 tumors in N-stage downstaging.